BR112012014059A8 - gel transdérmico de progestina / estradiol. - Google Patents

gel transdérmico de progestina / estradiol.

Info

Publication number
BR112012014059A8
BR112012014059A8 BR112012014059A BR112012014059A BR112012014059A8 BR 112012014059 A8 BR112012014059 A8 BR 112012014059A8 BR 112012014059 A BR112012014059 A BR 112012014059A BR 112012014059 A BR112012014059 A BR 112012014059A BR 112012014059 A8 BR112012014059 A8 BR 112012014059A8
Authority
BR
Brazil
Prior art keywords
progestin
estradiol
transdermal gel
potential
women
Prior art date
Application number
BR112012014059A
Other languages
English (en)
Other versions
BR112012014059B1 (pt
BR112012014059A2 (pt
Inventor
Grenier Arnaud
Norberto Ramon Carrara Dario
Sitruk-Ware Regine
Original Assignee
Antares Pharma Ipl Ag
The Population Council Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antares Pharma Ipl Ag, The Population Council Inc filed Critical Antares Pharma Ipl Ag
Publication of BR112012014059A2 publication Critical patent/BR112012014059A2/pt
Publication of BR112012014059A8 publication Critical patent/BR112012014059A8/pt
Publication of BR112012014059B1 publication Critical patent/BR112012014059B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

gel transdérmico de progestina/estradiol. a invenção revela composições e métodos para garantir tanto em mulheres em idade fértil uma contracepção em benefícios adicionais à saúde, quanto em mulheres em pós-menopausa, oferecendo uma terapia hormonal com benefícios médicos adicionais tais como o potencial para menor risco de trombose. as composições anteriormente mencionadas compreendendo nes como um agente progestacional e anti-ovulatório potente sem efeitos androgênicos ou estrogênicos ou glicocorticóide,e combinado com estradiol para administração não oral transdérmica como dosagem diárias específicas.
BR112012014059-0A 2009-12-17 2010-12-17 Gel transdérmico de progestina / estradiol BR112012014059B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28751409P 2009-12-17 2009-12-17
US61/287,514 2009-12-17
PCT/US2010/060941 WO2011084668A1 (en) 2009-12-17 2010-12-17 Nestorone®/estradiol transdermal gel

Publications (3)

Publication Number Publication Date
BR112012014059A2 BR112012014059A2 (pt) 2016-07-05
BR112012014059A8 true BR112012014059A8 (pt) 2017-12-26
BR112012014059B1 BR112012014059B1 (pt) 2020-03-10

Family

ID=43640394

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014059-0A BR112012014059B1 (pt) 2009-12-17 2010-12-17 Gel transdérmico de progestina / estradiol

Country Status (14)

Country Link
US (1) US9682087B2 (pt)
EP (1) EP2512486B1 (pt)
JP (1) JP6082249B2 (pt)
KR (2) KR101928321B1 (pt)
CN (1) CN102753180A (pt)
AU (1) AU2010339867B2 (pt)
BR (1) BR112012014059B1 (pt)
CA (1) CA2782075C (pt)
ES (1) ES2641613T3 (pt)
IN (1) IN2012DN04867A (pt)
MX (1) MX363536B (pt)
NZ (1) NZ600907A (pt)
WO (1) WO2011084668A1 (pt)
ZA (1) ZA201204267B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN102657661A (zh) * 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2648470C2 (ru) * 2016-03-03 2018-03-26 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP4313318A1 (en) * 2021-03-30 2024-02-07 Viatris Inc. Transdermal systems having low dose estrogen and methods of making and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1093816A3 (en) 1990-06-01 2003-10-22 The Population Council, Inc. Use of ST1435 in hormonal therapy by transdermal application
US5198223A (en) * 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
JPH04342531A (ja) 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収製剤
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US10052335B2 (en) * 2009-10-19 2018-08-21 The Population Council, Inc. Neuroprotection and myelin repair using Nestorone®

Also Published As

Publication number Publication date
BR112012014059B1 (pt) 2020-03-10
CA2782075A1 (en) 2011-07-14
EP2512486A1 (en) 2012-10-24
CA2782075C (en) 2015-06-30
ES2641613T3 (es) 2017-11-10
KR20120107492A (ko) 2012-10-02
KR20180084149A (ko) 2018-07-24
CN102753180A (zh) 2012-10-24
MX363536B (es) 2019-03-27
US20130045953A1 (en) 2013-02-21
AU2010339867B2 (en) 2014-07-24
JP2013514984A (ja) 2013-05-02
US9682087B2 (en) 2017-06-20
IN2012DN04867A (pt) 2015-09-25
NZ600907A (en) 2013-11-29
AU2010339867A1 (en) 2012-07-19
ZA201204267B (en) 2013-01-31
JP6082249B2 (ja) 2017-02-15
WO2011084668A1 (en) 2011-07-14
EP2512486B1 (en) 2017-06-28
BR112012014059A2 (pt) 2016-07-05
MX2012006755A (es) 2012-11-23
KR101928321B1 (ko) 2018-12-12

Similar Documents

Publication Publication Date Title
BR112012014059A8 (pt) gel transdérmico de progestina / estradiol.
BRPI0713257B8 (pt) sistema terapêutico transdérmico para a aplicação de norelgestromina
PL2131847T3 (pl) Lek zawierający przynajmniej jeden gestagen
BR112017022861A2 (pt) ligantes de decompostos receptores de andrógeno seletivos (sard) e métodos de utilização dos mesmos
GEP20105066B (en) Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
EA201000312A1 (ru) Композиции dhea для лечения менопаузы
GB201104241D0 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
MY161549A (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
ME00292B (me) Drospirenon za terapiju zamjene hormona
MX2012012026A (es) Formas de dosificacion solidas orales con dosis muy bajas para la hrt.
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
BR112014018439A8 (pt) Terapias de reposição de hormônio transdérmica
BR112014027942A2 (pt) dispersão de pó pró-lipossomal; composição farmacêutica; forma de dosagem oral; e método para tratar um indivíduo que necessite de terapia de testosterona
CO6660506A2 (es) Derivados de 6.7-dihidro -5h-benzon [7]anulenos, métodos para su preparación, preparaciones farmaceúticas que los contiene y su uso para la preparación de medicamentos
TN2014000247A1 (en) 6,7-dihydro-5h-benzo[7]annulene derivatives, methods for the production thereof, pharmaceutical preparations that contain said 6,7-dihydro-5h-benzo[7]annulene derivatives, and use thereof to produce drugs
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
NZ589444A (en) NON-HORMONAL STEROID MODULATORS OF NF-Kappa B FOR TREATMENT OF DISEASE
AR065585A1 (es) Antagonistas del receptor de mineralocorticoides para el tratamiento de endometriosis uso
BRPI0511864A (pt) uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento
MX2022000747A (es) Compuestos de estra-1,3,5(10)-trien-17-ona sustituida con 15.beta.-[3-propanamido] y sus 17-oximas para usarse en la inhibicion de 17.beta.-hidroxiesteroides deshidrogenasas.
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
AR070302A1 (es) Composicion farmaceutica de un sistema de liberacion vaginal de esteroides
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest
AR089839A1 (es) Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: THE POPULATION COUNCIL INC. (US)